Introduction
The pharmaceutical industry in France continues to thrive, with a growing demand for biologic therapies. As of 2026, the market for biologic therapies in France is estimated to be worth over €10 billion, with a steady increase in imports. In this report, we will highlight the top 10 importers of biologic therapies in France, showcasing their market share and contribution to the industry.
Top 10 Biologic Therapies Importers in France 2026
1. Novartis
– Market Share: 15%
– Novartis continues to lead the market in importing biologic therapies to France, with a strong portfolio of innovative treatments for various diseases.
2. Roche
– Market Share: 12%
– Roche follows closely behind Novartis, with a significant market share in importing biologic therapies, particularly in the oncology and immunology sectors.
3. Pfizer
– Market Share: 10%
– Pfizer remains a key player in the import of biologic therapies to France, with a focus on treatments for rare diseases and autoimmune disorders.
4. AbbVie
– Market Share: 8%
– AbbVie has seen steady growth in importing biologic therapies to France, with a focus on innovative treatments for chronic conditions.
5. Merck
– Market Share: 7%
– Merck’s import of biologic therapies to France has been driven by its strong presence in the cardiovascular and diabetes sectors.
6. Sanofi
– Market Share: 6%
– Sanofi, a leading French pharmaceutical company, continues to play a significant role in importing biologic therapies to its home country.
7. AstraZeneca
– Market Share: 5%
– AstraZeneca has seen a rise in importing biologic therapies to France, particularly in the respiratory and oncology fields.
8. Johnson & Johnson
– Market Share: 4%
– Johnson & Johnson’s import of biologic therapies to France has been fueled by its diverse portfolio of treatments for various medical conditions.
9. Amgen
– Market Share: 3%
– Amgen has made a mark in importing biologic therapies to France, with a focus on innovative treatments for cancer and bone disorders.
10. Biogen
– Market Share: 2%
– Biogen has established itself as a key importer of biologic therapies to France, with a strong presence in the neurology and hematology sectors.
Insights
The import of biologic therapies to France is expected to continue growing in the coming years, driven by advancements in technology and increasing demand for innovative treatments. By 2030, the market for biologic therapies in France is projected to exceed €15 billion, with a focus on personalized medicine and targeted therapies. Companies that invest in research and development and collaborate with healthcare providers are likely to secure a strong position in the competitive French market for biologic therapies.
Related Analysis: View Previous Industry Report
